EUVIMEDEUVIMED entdecken
Crossref

Effects of Sodium–Glucose Cotransporter 2 Inhibitor Use on Mortality, Amputation, and Healing in Patients With Diabetic Foot Ulcer

Clothilde Dumortier, Serge Aho Glele, Alexia Rouland, Lina Houbachi, Coralie Fourmont, Bruno Vergès iD, Jean Michel Petit iD, Benjamin Bouillet iD

Diabetes Care · 2026

DOI: 10.2337/dc25-2001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Care, 2026. Verfasst von Clothilde Dumortier und 7 weiteren Autor:innen. Beteiligte Einrichtung: Université Bourgogne Europe, CHU Dijon Bourgogne, Service Endocrinologie, Diabétologie, Nutrition, Dijon, France. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Amputation, Surgical, Diabetic Foot, Wound Healing. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE Diabetic foot ulcer (DFU) is the leading cause of nontraumatic lower-limb amputation (LLA). The impact of sodium–glucose cotransporter 2 inhibitor (SGLT2i) use on LLA is still debated in studies in which the proportion of patients with DFU is unknown. The aim of our study was to determine, specifically in patients with DFU, if the use of an SGLT2i could influence amputation and wound healing. RESEARCH DESIGN AND METHODS This retrospective, monocentric study was conducted in a French specialized diabetic foot center. All patients treated for a new DFU between January 2022 and May 2024 and who had 1 year of follow-up were included. The primary end point was 1-year amputation rate. RESULTS Of the 452 patients included in this study, 94 were treated with an SGLT2i and 358 were not. The mean ± SD age of the study population was 70.2 ± 11.6 years and 77% of patients were men. In the adjusted statistical model, there was no significant association between the 1-year amputation rate and SGLT2i use (P = 0.688). The 6-month healing rate was not significantly different between patients treated or not treated with SGLT2is (54.4% vs. 44.5%; P = 0.091). Healing time was significantly less in patients treated with SGLT2is, with a mean ± SD difference of 44 days (136.5 ± 97.8 vs. 181.2 ± 159.8; P = 0.04). The 1-year mortality rate was significantly lower in the SGLT2i group (1.1% vs. 9.2%; P = 0.009). CONCLUSIONS The use of SGLT2is does not negatively impact the 1-year amputation rate or healing rate of DFU. One-year mortality was lower in patients treated with an SGLT2i.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsAmputation, SurgicalDiabetic FootWound HealingHumansMaleRetrospective StudiesFemaleAgedMiddle AgedAged, 80 and over

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Université Bourgogne Europe, CHU Dijon Bourgogne, Service Endocrinologie, Diabétologie, Nutrition, Dijon, France.
  • Université Bourgogne Europe, CHU Dijon Bourgogne, Service Épidémiologie, Dijon, France.
  • Université Bourgogne Europe, CHU Dijon Bourgogne, Service Endocrinologie, Diabétologie, Nutrition, INSERM, CTM UMR U1231, Equipe Padys, Dijon, France.

ORCID-Profile: Bruno Vergès, Jean Michel Petit, Benjamin Bouillet

Zitieren

APA

Dumortier, C., Aho Glele, S., Rouland, A., Houbachi, L., Fourmont, C., Vergès, B., Petit, J. M., & Bouillet, B. (2026). Effects of Sodium–Glucose Cotransporter 2 Inhibitor Use on Mortality, Amputation, and Healing in Patients With Diabetic Foot Ulcer. Diabetes Care. https://doi.org/10.2337/dc25-2001

Vancouver

Dumortier C, Aho Glele S, Rouland A, Houbachi L, Fourmont C, Vergès B, et al. Effects of Sodium–Glucose Cotransporter 2 Inhibitor Use on Mortality, Amputation, and Healing in Patients With Diabetic Foot Ulcer. Diabetes Care. 2026. doi:10.2337/dc25-2001

BibTeX
@article{Dumortier2026,
  author = {Dumortier, Clothilde and Aho Glele, Serge and Rouland, Alexia and Houbachi, Lina and Fourmont, Coralie and Vergès, Bruno and Petit, Jean Michel and Bouillet, Benjamin},
  title = {Effects of Sodium–Glucose Cotransporter 2 Inhibitor Use on Mortality, Amputation, and Healing in Patients With Diabetic Foot Ulcer},
  journal = {Diabetes Care},
  year = {2026},
  doi = {10.2337/dc25-2001}
}
Kostenlos starten →